Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov-Dec;66(6):691-5.
doi: 10.1016/j.ihj.2014.12.009. Epub 2014 Dec 23.

A prospective, multi-centric, observational registry to evaluate performance of Excel™ DES in 'real world, all comers' patient population

Shirish Hiremath  1 , Praveen Chandra  2 , Devang Desai  3 , R Sivakumar  4 , S Selvamani  4 , Anand Srinivasan  5 , Madhu Paulose  5 , Sajy Jose  5 , B C Kalmath  6 , Vilas P Magarkar  7 , Abhijeet Pathak  8 , Tushar Mhetre  9
Affiliations

A prospective, multi-centric, observational registry to evaluate performance of Excel™ DES in 'real world, all comers' patient population

Shirish Hiremath et al. Indian Heart J. 2014 Nov-Dec.

Abstract

Objectives: This study aims to assess the safety and efficacy of a biodegradable polymer-coated Rapamycin-Eluting Stent (Excel) used in conjunction with six-month dual antiplatelet therapy in daily practice.

Background: The polymeric material of cardiac stents has been reported to adversely affect the safety profile of the drug-eluting stents and is also suspected to cause serious long-term complications. It has been proposed that the biodegradable polymer coatings may reduce such late-stage adverse effects.

Methods: This is a prospective, multi-center registry of 654 patients from across 9 cardiology centers in India, who were enrolled and exclusively treated with Excel stents between February 2008 and May 2010. The recommended antiplatelet regimen included clopidogrel and aspirin for 6 months period, followed by lifelong aspirin therapy.

Results: The study population included 46.94% diabetics, 24.31% smokers, 48.93% hypertensives and 14.98% hyperlipidemics. The cumulative rates of major adverse cardiac events were 0.153% at discharge and 1.38% at 12 months. The mean percentage of stenosis was 88.24 ± 9.17% No events occurred between 6 and 12 months.

Conclusions: This multi-center registry study on "real world, all comers" has, thus, showed that EXCEL™ stent which is PLA-coated biodegradable Rapamycin-Eluting Stent exhibited high efficacy and safety profile in treatment of patients undergoing PCI as evidenced by significantly lower rates of MACE and no case of stent thrombosis. There was no event even after DAPT was discontinued after 6 months.

Keywords: DAPT; DES; Excel; MACE; Rapamycin.

PubMed Disclaimer

References

    1. Babapulle M.N., Joseph L., Belisle P. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583–591. - PubMed
    1. Moses J.W., Leon M.B., Popma J.J., on behalf of SIRIUS Investigators Rapamycin-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323. - PubMed
    1. Stone G.W., Ellis S.G., Cox D.A., on behalf of TAXUS-IV Investigators One-year clinical results with the slow-release, polymer based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947. - PubMed
    1. McFadden E.P., Stabile E., Regar E. Late thrombosis in drug-eluting coronary stents after discontinuation of anti-platelet therapy. Lancet. 2004;364:1519–1521. - PubMed
    1. Liistro F., Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. 2001;86:262–264. - PMC - PubMed